Metastatic renal cell carcinoma: Radiologic findings and assessment of response to targeted antiangiogenic therapy by using multidetector CT

Radiographics

Volumn 33, Issue 6, 2013, Pages 1691-1716

  Brufau, Blanca Paño ^a   Cerqueda, Carmen Sebastià ^a   Villalba, Laura Buñesch ^a   Izquierdo, Rafael Salvador ^a   González, Begoña Mellado ^a   Molina, Carlos Nicolau ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR;

ARTICLE; DISEASE COURSE; HUMAN; KIDNEY CARCINOMA; KIDNEY TUMOR; METASTASIS; MULTIDETECTOR COMPUTED TOMOGRAPHY; PATHOLOGY; PROGNOSIS; RADIOGRAPHY;

ANGIOGENESIS INHIBITORS; CARCINOMA, RENAL CELL; DISEASE PROGRESSION; HUMANS; KIDNEY NEOPLASMS; MULTIDETECTOR COMPUTED TOMOGRAPHY; NEOPLASM METASTASIS; PROGNOSIS;

EID: 84885353682     PISSN: 02715333     EISSN: 15271323     Source Type: Journal    
DOI: 10.1148/rg.336125110     Document Type: Article

References (87)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62(1):10-29.
2. Janzen NK, Kim HL, Figlin RA, Belldegrun AS. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am 2003;30(4): 843-852.
3. Sandock DS, Seftel AD, Resnick MI. A new protocol for the followup of renal cell carcinoma based on pathological stage. J Urol 1995;154(1):28-31.
4. Thyavihally YB, Mahantshetty U, Chamarajanagar RS, Raibhattanavar SG, Tongaonkar HB. Management of renal cell carcinoma with solitary metastasis. World J Surg Oncol 2005;3:48.
5. O'dea MJ, Zincke H, Utz DC, Bernatz PE. The treatment of renal cell carcinoma with solitary metastasis. J Urol 1978;120(5):540-542.
6. Rafla S. Renal cell carcinoma: natural history and results of treatment. Cancer 1970;25(1):26-40.
7. Hafez KS, Novick AC, Campbell SC. Patterns of tumor recurrence and guidelines for followup after nephron sparing surgery for sporadic renal cell carcinoma. J Urol 1997;157(6):2067-2070.
8. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010;17(6):1471-1474.
9. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982;6(7):655-663.
10. Motzer RJ, Bacik J, Mariani T, Russo P, Mazumdar M, Reuter V. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol 2002;20(9): 2376-2381.
11. Cheville JC, Lohse CM, Zincke H, et al. Sarcomatoid renal cell carcinoma: an examination of underlying histologic subtype and an analysis of associations with patient outcome. Am J Surg Pathol 2004; 28(4):435-441.
12. Lombardi G, Zustovich F, Donach M, Dalla Palma M, Nicoletto O, Pastorelli D. An update on targeted therapy in metastatic renal cell carcinoma. Urol Oncol 2012;30(3):240-246.
13. Debois JM. Metastases from cancers of the urogenital tract. In: TXNXM1: the anatomy and clinics of metastatic cancer. Boston, Mass: Kluwer Academic Publishers, 2002; 456-579.
14. Ng CS, Wood CG, Silverman PM, Tannir NM, Tamboli P, Sandler CM. Renal cell carcinoma: diagnosis, staging, and surveillance. AJR Am J Roentgenol 2008;191(4):1220-1232.
15. Valappil SV, Toon PG, Anandaram PS. Ovarian metastasis from primary renal cell carcinoma: report of a case and review of literature. Gynecol Oncol 2004; 94(3):846-849.
16. Raptopoulos VD, Blake SP, Weisinger K, Atkins MB, Keogan MT, Kruskal JB. Multiphase contrast-enhanced helical CT of liver metastases from renal cell carcinoma. Eur Radiol 2001;11(12):2504-2509.
17. Ng CS, Loyer EM, Iyer RB, David CL, DuBrow RA, Charnsangavej C. Metastases to the pancreas from renal cell carcinoma: findings on three-phase contrast-enhanced helical CT. AJR Am J Roentgenol 1999;172(6):1555-1559.
18. Griffin N, Gore ME, Sohaib SA. Imaging in metastatic renal cell carcinoma. AJR Am J Roentgenol 2007;189(2):360-370.
19. Jain Y, Liew S, Taylor MB, Bonington SC. Is dual-phase abdominal CT necessary for the optimal detection of metastases from renal cell carcinoma? Clin Radiol 2011;66(11):1055-1059.
20. Wang JH, Min PQ, Wang PJ, et al. Dynamic CT evaluation of tumor vascularity in renal cell carcinoma. AJR Am J Roentgenol 2006;186(5): 1423-1430.
21. Kim JK, Kim TK, Ahn HJ, Kim CS, Kim KR, Cho KS. Differentiation of subtypes of renal cell carcinoma on helical CT scans. AJR Am J Roentgenol 2002;178(6):1499-1506.
22. Vikram R, Ng CS, Tamboli P, et al. Papillary renal cell carcinoma: radiologic-pathologic correlation and spectrum of disease. RadioGraphics 2009;29 (3):741-754; discussion 755-757.
23. Bianchi M, Sun M, Jeldres C, et al. Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. Ann Oncol 2012;23(4):973-980.
24. Saitoh H, Nakayama M, Nakamura K, Satoh T. Distant metastasis of renal adenocarcinoma in nephrectomized cases. J Urol 1982;127(6):1092-1095.
25. Katta A, Fesler MJ, Tan A, Vuong G, Richart JM. Spontaneous bilateral pneumothorax in metastatic renal cell carcinoma on sunitinib therapy. Cancer Chemother Pharmacol 2010;66(2):409-412.
26. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001;345(23): 1655-1659.
27. Woodward E, Jagdev S, McParland L, et al. Skeletal complications and survival in renal cancer patients with bone metastases. Bone 2011;48(1):160-166.
28. Zekri J, Ahmed N, Coleman RE, Hancock BW. The skeletal metastatic complications of renal cell carcinoma. Int J Oncol 2001;19(2):379-382.
29. Jung ST, Ghert MA, Harrelson JM, Scully SP. Treatment of osseous metastases in patients with renal cell carcinoma. Clin Orthop Relat Res 2003; (409):223-231.
30. Lin PP, Mirza AN, Lewis VO, et al. Patient survival after surgery for osseous metastases from renal cell carcinoma. J Bone Joint Surg Am 2007;89(8): 1794-1801.
31. Reznek RH. CT/MRI in staging renal cell carcinoma. Cancer Imaging 2004;4(Spec No A):S25-S32.
32. Koh DM, Hughes M, Husband JE. Cross-sectional imaging of nodal metastases in the abdomen and pelvis. Abdom Imaging 2006;31(6):632-643.
33. Paño B, Sebastià C, Buñesch L, et al. Pathways of lymphatic spread in male urogenital pelvic malignancies. RadioGraphics 2011;31(1):135-160.
34. Pantuck AJ, Zisman A, Dorey F, et al. Renal cell carcinoma with retroperitoneal lymph nodes: impact on survival and benefits of immunotherapy. Cancer 2003;97(12):2995-3002.
35. Johnsen JA, Hellsten S. Lymphatogenous spread of renal cell carcinoma: an autopsy study. J Urol 1997;157(2):450-453.
36. Renshaw AA, Richie JP. Subtypes of renal cell carcinoma: different onset and sites of metastatic disease. Am J Clin Pathol 1999;111(4):539-543.
37. Aloia TA, Adam R, Azoulay D, Bismuth H, Castaing D. Outcome following hepatic resection of metastatic renal tumors: the Paul Brousse Hospital experience. HPB (Oxford) 2006;8(2):100-105.
38. Gill IS, McClennan BL, Kerbl K, Carbone JM, Wick M, Clayman RV. Adrenal involvement from renal cell carcinoma: predictive value of computerized tomography. J Urol 1994;152(4):1082-1085.
39. von Knobloch R, Hegele A, Kälble T, Hofmann R. Management of contralateral adrenal metastasis from renal cell carcinoma: possibility of inferior vena cava tumour thrombus. Scand J Urol Nephrol 2000; 34(2):109-113.
40. Mori Y, Kondziolka D, Flickinger JC, Logan T, Lunsford LD. Stereotactic radiosurgery for brain metastasis from renal cell carcinoma. Cancer 1998; 83(2):344-353.
41. Hoshi S, Jokura H, Nakamura H, et al. Gamma-knife radiosurgery for brain metastasis of renal cell carcinoma: results in 42 patients. Int J Urol 2002;9 (11):618-625; discussion 626-627.
42. Ljungberg B, Alamdari FI, Rasmuson T, Roos G. Follow-up guidelines for nonmetastatic renal cell carcinoma based on the occurrence of metastases after radical nephrectomy. BJU Int 1999;84(4): 405-411.
43. Wroński M, Arbit E, Russo P, Galicich JH. Surgical resection of brain metastases from renal cell carcinoma in 50 patients. Urology 1996;47(2):187-193.
44. Schellinger PD, Meinck HM, Thron A. Diagnostic accuracy of MRI compared to CCT in patients with brain metastases. J Neurooncol 1999;44(3):275-281.
45. Shuch B, La Rochelle JC, Klatte T, et al. Brain metastasis from renal cell carcinoma: presentation, recurrence, and survival. Cancer 2008;113(7): 1641-1648.
46. Tartar VM, Heiken JP, McClennan BL. Renal cell carcinoma presenting with diffuse peritoneal metastases: CT findings. J Comput Assist Tomogr 1991; 15(3):450-453.
47. Adsay NV, Andea A, Basturk O, Kilinc N, Nassar H, Cheng JD. Secondary tumors of the pancreas: an analysis of a surgical and autopsy database and review of the literature. Virchows Arch 2004;444(6): 527-535.
48. Kassabian A, Stein J, Jabbour N, et al. Renal cell carcinoma metastatic to the pancreas: a single-institution series and review of the literature. Urology 2000;56(2):211-215.
49. Sellner F, Tykalsky N, De Santis M, Pont J, Klimpfinger M. Solitary and multiple isolated metastases of clear cell renal carcinoma to the pancreas: an indication for pancreatic surgery. Ann Surg Oncol 2006;13(1):75-85.
50. Moir JA, Sen G, Saif R, Haugk B, French JJ. Isolated splenic metastasis from renal cell carcinoma: case report and review. Case Rep Gastroenterol 2011;5(1):166-171.
51. Kamiyoshihara M, Ibe T, Takise A, Itou H, Takeyoshi I. Pleural metastases from renal cell carcinoma 16 years after resection. J Clin Oncol 2007;25(25): 4009-4011.
52. Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005;(1): CD001425.
53. Cuenod CA, Fournier L, Balvay D, Guinebretière JM. Tumor angiogenesis: pathophysiology and implications for contrast-enhanced MRI and CT assessment. Abdom Imaging 2006;31(2):188-193.
54. Verma S, Rajesh A, Fütterer JJ, et al. Prostate MRI and 3D MR spectroscopy: how we do it. AJR Am J Roentgenol 2010;194(6):1414-1426.
55. Figueiras RG, Padhani AR, Goh VJ, et al. Novel oncologic drugs: what they do and how they affect images. RadioGraphics 2011;31(7):2059-2091.
56. Zee YK, O'Connor JP, Parker GJ, et al. Imaging angiogenesis of genitourinary tumors. Nat Rev Urol 2010;7(2):69-82.
57. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45(2):228-247.
58. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356(2):115-124.
59. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356(2):125-134.
60. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007;370(9605): 2103-2111.
61. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27 (22):3584-3590.
62. Thiam R, Fournier LS, Trinquart L, et al. Optimizing the size variation threshold for the CT evaluation of response in metastatic renal cell carcinoma treated with sunitinib. Ann Oncol 2010;21(5): 936-941.
63. Jinzaki M, Tanimoto A, Mukai M, et al. Double-phase helical CT of small renal parenchymal neoplasms: correlation with pathologic findings and tumor angiogenesis. J Comput Assist Tomogr 2000;24 (6):835-842.
64. Miles KA. Tumour angiogenesis and its relation to contrast enhancement on computed tomography: a review. Eur J Radiol 1999;30(3):198-205.
65. Han KS, Jung DC, Choi HJ, et al. Pretreatment assessment of tumor enhancement on contrast-enhanced computed tomography as a potential predictor of treatment outcome in metastatic renal cell carcinoma patients receiving antiangiogenic therapy. Cancer 2010;116(10):2332-2342.
66. Baccala A Jr, Hedgepeth R, Kaouk J, Magi-Galluzzi C, Gilligan T, Fergany A. Pathological evidence of necrosis in recurrent renal mass following treatment with sunitinib. Int J Urol 2007;14(12):1095-1097; discussion 1097.
67. Smith AD, Lieber ML, Shah SN. Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT. AJR Am J Roentgenol 2010;194(1):157-165.
68. Choi H. Response evaluation of gastrointestinal stromal tumors. Oncologist 2008;13(suppl 2):4-7.
69. van der Veldt AA, Meijerink MR, van den Eertwegh AJ, Haanen JB, Boven E. Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. Br J Cancer 2010;102(5):803-809.
70. Nathan PD, Vinayan A, Stott D, Juttla J, Goh V. CT response assessment combining reduction in both size and arterial phase density correlates with time to progression in metastatic renal cancer patients treated with targeted therapies. Cancer Biol Ther 2010;9(1):15-19.
71. Juttla JK, Goh VJ, Nathan P, Vinayan A. Size and enhancement response criteria for TKIs in metastatic renal cell cancer: does arterial or portal venous phase imaging alter response categorization? [abstr]. In: Radiological Society of North America Scientific Assembly and Annual Meeting Program. Oak Brook, Ill: Radiological Society of North America, 2010; 392.
72. Smith AD, Shah SN, Rini BI, Lieber ML, Remer EM. Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy. AJR Am J Roentgenol 2010;194(6):1470-1478.
73. van der Veldt AA, Meijerink MR, van den Eertwegh AJ, Boven E. Targeted therapies in renal cell cancer: recent developments in imaging. Target Oncol 2010;5(2):95-112.
74. Chen Y, Zhang J, Dai J, Feng X, Lu H, Zhou C. Angiogenesis of renal cell carcinoma: perfusion CT findings. Abdom Imaging 2010;35(5):622-628.
75. Schor-Bardach R, Alsop DC, Pedrosa I, et al. Does arterial spin-labeling MR imaging-measured tumor perfusion correlate with renal cell cancer response to antiangiogenic therapy in a mouse model? Radiology 2009;251(3):731-742.
76. de Bazelaire C, Alsop DC, George D, et al. Magnetic resonance imaging-measured blood flow change after antiangiogenic therapy with PTK787/ZK 222584 correlates with clinical outcome in metastatic renal cell carcinoma. Clin Cancer Res 2008; 14(17):5548-5554.
77. Forsberg F. Can the effect of antiangiogenic treatments be monitored and quantified noninvasively by using contrast-enhanced US? Radiology 2010;254 (2):317-318.
78. Reiner CS, Goetti R, Eberli D, et al. CT perfusion of renal cell carcinoma: impact of volume coverage on quantitative analysis. Invest Radiol 2012;47(1): 33-40.
79. Goh V, Ng QS, Miles K. Computed tomography perfusion imaging for therapeutic assessment: has it come of age as a biomarker in oncology? Invest Radiol 2012;47(1):2-4.
80. Goh V, Dattani M, Farwell J, et al. Radiation dose from volumetric helical perfusion CT of the thorax, abdomen or pelvis. Eur Radiol 2011;21(5):974-981.
81. García Figueiras R, Padhani AR, Vilanova JC, Goh V, Villalba Martín C. Functional imaging of tumors, part 1 [in Spanish]. Radiologia 2010;52(2):115-125.
82. Ng CS, Chandler AG, Wei W, et al. Reproducibility of CT perfusion parameters in liver tumors and normal liver. Radiology 2011;260(3):762-770.
83. Kudo K, Sasaki M, Yamada K, et al. Differences in CT perfusion maps generated by different commercial software: quantitative analysis by using identical source data of acute stroke patients. Radiology 2010;254(1):200-209.
84. Fournier LS, Oudard S, Thiam R, et al. Metastatic renal carcinoma: evaluation of antiangiogenic therapy with dynamic contrast-enhanced CT. Radiology 2010;256(2):511-518.
85. Maksimovic O, Schraml C, Hartmann JT, et al. Evaluation of response in malignant tumors treated with the multitargeted tyrosine kinase inhibitor sorafenib: a multitechnique imaging assessment. AJR Am J Roentgenol 2010;194(1):5-14.
86. Sabir A, Schor-Bardach R, Wilcox CJ, et al. Perfusion MDCT enables early detection of therapeutic response to antiangiogenic therapy. AJR Am J Roentgenol 2008;191(1):133-139.
87. Miles KA, Lee TY, Goh V, et al. Current status and guidelines for the assessment of tumour vascular support with dynamic contrast-enhanced computed tomography. Eur Radiol 2012;22(7):1430-1441.